Abeona Therapeutics (NASDAQ:ABEO) Announces Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Abeona Therapeutics (NASDAQ:ABEO) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09, FiscalAI reports. The business had revenue of $13.49 million for the quarter, compared to analysts’ expectations of $14.82 million.

Here are the key takeaways from Abeona Therapeutics’ conference call:

• ZEVASKYN revenue rose 18% sequentially to $13.5 million, with six patients treated during the quarter and 15 treated since launch. The network expanded to eight qualified treatment centers, four of which have treated patients.
• Patient treatment timing remains variable as patients and centers work through authorization, scheduling, and other steps; a planned manufacturing shutdown from mid-November to mid-January is expected to shift some treatments into 2027. The company reported one out-of-specification batch among 15 treated patients and is not providing patient-funnel numbers.
• Abeona acquired ABO-801, a phase III-stage EoE candidate, for $20 million in stock, with additional approval and commercial milestone payments and tiered royalties owed to Ellodi. Management sees potential for peak annual revenue above $750 million and plans a roughly 400-patient phase III trial, pending FDA feedback, with initiation expected in mid-2027.
• ABO-801 showed histologic and endoscopic activity in prior trials, but neither study individually met its co-primary symptom endpoint; management attributes this in part to the symptom-assessment tool and plans to use the DSQ in the next trial. The company estimates $50 million–$60 million to develop the drug through approval and says its cash, private-placement proceeds, expected ZEVASKYN sales, and FAYUVI royalties provide funding support.

Abeona Therapeutics Trading Down 39.1%

Shares of NASDAQ:ABEO opened at $2.54 on Tuesday. Abeona Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.65. The company has a market capitalization of $145.24 million, a PE ratio of -2.33 and a beta of 1.50. The business has a 50 day moving average of $4.98 and a two-hundred day moving average of $5.45. The company has a current ratio of 6.63, a quick ratio of 6.40 and a debt-to-equity ratio of 0.01.

Abeona Therapeutics News Roundup

Here are the key news stories impacting Abeona Therapeutics this week:

• Positive Sentiment: Abeona acquired APT-1011, now called ABO-801, a once-daily oral eosinophilic esophagitis (EoE) candidate described as Phase 3-ready. The addition expands the pipeline with a potential new treatment opportunity. Read More.
• Positive Sentiment: ZEVASKYN net revenue reached $13.5 million in Q3, up 18% sequentially from Q2. The company reported 15 treatments completed since launch, including six in Q3, and expansion of its treatment-center network to eight sites. Read More.
• Neutral Sentiment: The company reported a Q3 loss of $0.08 per share, narrower than analysts’ expected $0.14 loss. Cash, cash equivalents and short-term investments totaled $134.9 million at quarter-end. Read More.
• Negative Sentiment: Abeona agreed to raise $30 million in a private placement, which may dilute existing shareholders. Q3 revenue of $13.49 million was also below the $14.82 million analyst consensus, tempering the positive sales growth. Read More.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Weiss Ratings downgraded shares of Abeona Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, August 17th. Oppenheimer reiterated an “outperform” rating and issued a $21.00 price objective (down from $22.00) on shares of Abeona Therapeutics in a research note on Friday, August 14th. Wall Street Zen raised shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. Cantor Fitzgerald boosted their target price on shares of Abeona Therapeutics from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, September 18th. Finally, Roth Capital started coverage on shares of Abeona Therapeutics in a report on Thursday, September 17th. They issued a “buy” rating and a $17.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Insiders Place Their Bets

In other news, Director Mark Alvino sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $5.86, for a total transaction of $87,900.00. Following the sale, the director owned 62,065 shares of the company’s stock, valued at $363,700.90. This trade represents a 19.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Madhav Vasanthavada sold 4,902 shares of the firm’s stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $5.16, for a total transaction of $25,294.32. Following the sale, the insider directly owned 285,721 shares in the company, valued at $1,474,320.36. The trade was a 1.69% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 55,428 shares of company stock worth $296,508. Corporate insiders own 7.10% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc (NASDAQ: ABEO) is a biopharmaceutical company focused on developing and commercializing cell and gene therapies for serious and rare genetic diseases. The company’s programs are designed to address conditions with limited treatment options, including diseases caused by genetic defects affecting the skin and other tissues.

Abeona’s lead product, prademagene zamikeracel, is an autologous cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), a rare inherited disorder that causes fragile skin and chronic wounds.